(Ghent, Belgium) is an early-stage venture capital fund focusing on life science tools and technologies. The fund’s core competence lies in “enabling technologies” within research and manufacturing, genomics, bioinformatics, diagnostics, and personalized medicine.  Novalis focuses on capital light business models and close interaction to clients, leading to early commercial traction and validation of the business model. Since inception in 2019, Novalis has invested more than 15 companies, mainly in Western-Europe. Typical investment tickets range from 500kEUR to 2 mio EUR.